Physician profile
Lenee Joy Cayabyab
NPI 1558639716
$1,279.01
in general payments reported to CMS, 2019-2025
14 companies · $559 in 2025
The $559 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $720 · 2025: $559.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,183 · Education: $96.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,182.88 |
| Education | $96.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $405.88 | 2024-2025 | |
| Janssen Biotech, INC. | $206.10 | 2024-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $162.77 | 2024-2025 | Dupixent |
| Incyte Corporation | $99.24 | 2024-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $86.96 | 2024 | Sotyktu |
| Genzyme Corporation | $69.53 | 2024 | |
| Novartis Pharmaceuticals Corporation | $48.13 | 2024-2025 | |
| Dermavant Sciences, INC. | $41.48 | 2024 | Vtama |
| Biofrontera INC. | $41.12 | 2025 | |
| Leo Pharma INC. | $30.61 | 2025 | Anzupgo |
| Ucb, INC. | $27.62 | 2025 | Bimzelx |
| Lilly USA, LLC | $23.76 | 2025 | Ebglyss |
| Arcutis Biotherapeutics, INC. | $20.54 | 2024 | Zoryve |
| Pfizer INC. | $15.27 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lenee Cayabyab listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.